312 related articles for article (PubMed ID: 32799609)
1. GPR120 agonists for the treatment of diabetes: a patent review (2014 present).
Zhang X; Macielag MJ
Expert Opin Ther Pat; 2020 Oct; 30(10):729-742. PubMed ID: 32799609
[TBL] [Abstract][Full Text] [Related]
2. Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion.
Suckow AT; Polidori D; Yan W; Chon S; Ma JY; Leonard J; Briscoe CP
J Biol Chem; 2014 May; 289(22):15751-63. PubMed ID: 24742677
[TBL] [Abstract][Full Text] [Related]
3. A novel GPR120-selective agonist promotes insulin secretion and improves chronic inflammation.
Yang L; Lei XT; Huang Q; Wang T; Sun HB; Wang HY
Life Sci; 2021 Mar; 269():119029. PubMed ID: 33450256
[TBL] [Abstract][Full Text] [Related]
4. Potential roles of GPR120 and its agonists in the management of diabetes.
Zhang D; Leung PS
Drug Des Devel Ther; 2014; 8():1013-27. PubMed ID: 25114508
[TBL] [Abstract][Full Text] [Related]
5. Insulinotropic effects of GPR120 agonists are altered in obese diabetic and obese non-diabetic states.
Zhang D; So WY; Wang Y; Wu SY; Cheng Q; Leung PS
Clin Sci (Lond); 2017 Feb; 131(3):247-260. PubMed ID: 27980130
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the insulin-releasing and glucose-lowering effects of GPR120 activation in pancreatic β-cells.
Moran BM; Abdel-Wahab YH; Flatt PR; McKillop AM
Diabetes Obes Metab; 2014 Nov; 16(11):1128-39. PubMed ID: 24919766
[TBL] [Abstract][Full Text] [Related]
7. A new synthetic dual agonist of GPR120/GPR40 induces GLP-1 secretion and improves glucose homeostasis in mice.
Bianchini G; Nigro C; Sirico A; Novelli R; Prevenzano I; Miele C; Beguinot F; Aramini A
Biomed Pharmacother; 2021 Jul; 139():111613. PubMed ID: 33895521
[TBL] [Abstract][Full Text] [Related]
8. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice.
Oh DY; Walenta E; Akiyama TE; Lagakos WS; Lackey D; Pessentheiner AR; Sasik R; Hah N; Chi TJ; Cox JM; Powels MA; Di Salvo J; Sinz C; Watkins SM; Armando AM; Chung H; Evans RM; Quehenberger O; McNelis J; Bogner-Strauss JG; Olefsky JM
Nat Med; 2014 Aug; 20(8):942-7. PubMed ID: 24997608
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic potential of GPR120: a patent review.
Halder S; Kumar S; Sharma R
Expert Opin Ther Pat; 2013 Dec; 23(12):1581-90. PubMed ID: 24094095
[TBL] [Abstract][Full Text] [Related]
10. Development of novel ligands for peptide GPCRs.
Moran BM; McKillop AM; O'Harte FP
Curr Opin Pharmacol; 2016 Dec; 31():57-62. PubMed ID: 27607913
[TBL] [Abstract][Full Text] [Related]
11. Diphenyl Ether Derivatives as Novel GPR120 Agonists for the Treatment of Type 2 Diabetes Mellitus.
Wang X; Wei S; Wang M; Xu Y; Hu W; Niu M; Wang S; Lei K; Ji L; Liu R; Ji G
Chem Biodivers; 2023 Jan; 20(1):e202200814. PubMed ID: 36471492
[TBL] [Abstract][Full Text] [Related]
12. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
[TBL] [Abstract][Full Text] [Related]
13. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
Rani L; Grewal AS; Sharma N; Singh S
Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules.
Briscoe CP; Peat AJ; McKeown SC; Corbett DF; Goetz AS; Littleton TR; McCoy DC; Kenakin TP; Andrews JL; Ammala C; Fornwald JA; Ignar DM; Jenkinson S
Br J Pharmacol; 2006 Jul; 148(5):619-28. PubMed ID: 16702987
[TBL] [Abstract][Full Text] [Related]
15. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases.
Talukdar S; Olefsky JM; Osborn O
Trends Pharmacol Sci; 2011 Sep; 32(9):543-50. PubMed ID: 21663979
[TBL] [Abstract][Full Text] [Related]
16. GPR120 suppresses adipose tissue lipolysis and synergizes with GPR40 in antidiabetic efficacy.
Satapati S; Qian Y; Wu MS; Petrov A; Dai G; Wang SP; Zhu Y; Shen X; Muise ES; Chen Y; Zycband E; Weinglass A; Di Salvo J; Debenham JS; Cox JM; Lan P; Shah V; Previs SF; Erion M; Kelley DE; Wang L; Howard AD; Shang J
J Lipid Res; 2017 Aug; 58(8):1561-1578. PubMed ID: 28583918
[TBL] [Abstract][Full Text] [Related]
17. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
[TBL] [Abstract][Full Text] [Related]
18. Novel GPR120 Agonists with Improved Pharmacokinetic Profiles for the Treatment of Type 2 Diabetes.
Ji G; Guo Q; Xue Q; Kong R; Wang S; Lei K; Liu R; Wang X
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833999
[TBL] [Abstract][Full Text] [Related]
19. Lipid receptors and islet function: therapeutic implications?
Kebede MA; Alquier T; Latour MG; Poitout V
Diabetes Obes Metab; 2009 Nov; 11 Suppl 4(Suppl 4):10-20. PubMed ID: 19817784
[TBL] [Abstract][Full Text] [Related]
20. β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1.
Mancini AD; Bertrand G; Vivot K; Carpentier É; Tremblay C; Ghislain J; Bouvier M; Poitout V
J Biol Chem; 2015 Aug; 290(34):21131-21140. PubMed ID: 26157145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
